Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the benzenesulfonamide class, with the molecular formula C18H22ClN3O3S and a molecular weight of approximately 395.9 g/mol. It is an experimental drug that has not been approved for any indication. The primary known mechanism of action is inhibition of the enzyme 11-beta-hydroxysteroid dehydrogenase 1 (11β-HSD1), which plays a role in glucocorticoid metabolism by converting inactive cortisone to active cortisol. Inhibition of this enzyme has been investigated as a potential therapeutic strategy for metabolic disorders such as type 2 diabetes and obesity, but there are no reported clinical trials or approvals for this compound[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-(6-{[(3-chloro-2-methylphenyl)sulfonyl]amino}pyridin-2-yl)-N,N-diethylacetamide.